Deutsche Bank Aktiengesellschaft (NYSE:DB) tinted gains of +0.45% (+0.05 points) to US$11.2. The volume of 4.06 Million shares climbed down over an trading activity of 5.28 Million shares. EPS ratio determined by looking at last 12 month figures is -0.04. Over the same time span, the stock marked US$20.23 as its best level and the lowest price reached was US$10.36. The corporation has a market cap of US$21.96 Billion.
Deutsche Bank Aktiengesellschaft (NYSE:DB)’s earnings per share has been growing at a -3.3 percent rate over the past 5 year when average revenue increase was noted as -5.3 percent. The return on equity ratio or ROE stands at -2.2 percent while most common profitability ratio return on investment (ROI) was 3.4 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -6.2 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 5 analysts call it Sell, while 13 think it is Hold. Recently, analysts have updated the overall rating to 3.5. 0 analysts recommended Overweight these shares while 8 recommended Underweight, according to FactSet data.
TherapeuticsMD, Inc. (NASDAQ:TXMD) is worth US$1.4 Billion and has recently risen 0.45% to US$6.73. The latest exchange of 1.18 Million shares is below its average trading activity of 3.19 Million shares. The day began at US$6.69 but the price moved to US$6.54 at one point during the trading and finally capitulating to a session high of US$6.75. The stock tapped a 52-week high of US$7.66 while the mean 12-month price target for the shares is US$15.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 13.46, and a price to sales ratio of 84.6. For the past 5 years, the company’s revenue has grown 34.5%, while the company’s earnings per share has grown 0.5%. With an institutional ownership near 74%, it carries an earnings per share ratio of -0.38.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.62.